Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy

Natural History of Chemotherapy Induced Neuropathy.- Predisposing factors for the development of CIPN.- Evaluation of Chemotherapy-Induced Peripheral Neuropathy.- Preventive Strategies for Chemotherapy-in-duced Peripheral Neuropathy.- Prevention of CIPN - Current Clinical Data and Future Directions.- Treatment of established CIPN: basic science and animal models.- Pharmacological Treatment of Established CIPN.- Systematic review of exercise for prevention and management of chemotherapy-induced peripheral neuropathy.- Clinical and practical recommendations in the use of exercise, physical therapy, and occupational therapy for chemotherapy-induced peripheral neuropathy.- Natural course of neurotoxicity after immune checkpoint inhibitor (ICI) exposure.- Ants and Needles and Pins - Living with Neuropathy.

Maryam Lustberg, MD: Dr. Lustberg is an Associate Professor Division of Medical Oncology at The Ohio State University, where she specializes in treating patients with breast cancer and conducts NIH-funded research at Ohio State's Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James). She is chair on the Breast Cancer Survivorship Care Committee and is the Medical Director of Cancer Supportive Care Services. She is the President Elect of Multi National Association of Cancer Supportive Care (MASCC) and serves as Chair of MASCC Neurological Committee.Charles L Loprinzi, MD: Dr. Loprinzi, the endowed Regis Professor of Breast Cancer Research, is a medical oncologist who has been working at Mayo Clinic in Rochester Minnesota since 1985. He has been intimately involved in symptom control research, defined as research aimed at trying to prevent and/or treat and/or better understand symptoms related to cancer and or cancer therapy. A large part of this work has involved the topic of chemotherapy-induced neuropathy. Dr. Loprinzi has been intimately involved in the conduct of 8 cooperative group randomized, placebo-controlled, double-blinded, Phase III clinical trials, 4 to try to prevent CIPN and 4 to try to treat established CIPN. He has more than 50 publications related to chemotherapy neuropathy and has served as the co-chair of the American Society of Clinical Oncology (ASCO) chemotherapy-induced peripheral neuropathy guidelines on two occasions.